Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

Latest news

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

  • Tecentriq growth offsets Avastin's US decline at Roche Tecentriq growth offsets Avastin's US decline at Roche

    Roche is hoping that while Avastin is likely to see some cannibalisation of sales from Tecentriq, combination use could support its older drug. ... Overall, Roche reported a 3% increase in pharma sales to CHF 39bn, and the company is expecting low- to mid

  • AbbVie weak on new drug sales, but Humira stays strong AbbVie weak on new drug sales, but Humira stays strong

    AbbVie weak on new drug sales, but Humira stays strong. World’ s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short. ... Imbruvica - which is also sold by Johnson &Johnson - should hit $2.4bn in sales this year, of which

  • J&J pondering future of diabetes device assets J&J pondering future of diabetes device assets

    J&J pondering future of diabetes device assets. Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales. ... The diabetes care announcement came as J&J's fourth quarter sales fell below analyst estimates, with top-selling drug

  • Novartis 'reviewing options' for Alcon division Novartis 'reviewing options' for Alcon division

    Last year, chief executive Joe Jimenez set a deadline for Alcon to get sales back on track by the end of 2016, but fourth quarter sales were flat - even though the ... All told, Novartis reported a 2% decline in sales to $12.52bn in the quarter, with

More from news
Approximately 9 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics